Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
Risk & Volatility
Dr. Reddy’s Laboratories has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
Institutional and Insider Ownership
3.8% of Dr. Reddy’s Laboratories shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy’s Laboratories shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Dr. Reddy’s Laboratories and LENZ Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dr. Reddy’s Laboratories | 8.56% | 7.91% | 5.29% |
| LENZ Therapeutics | -1,134.97% | -56.10% | -51.63% |
Analyst Recommendations
This is a summary of current ratings for Dr. Reddy’s Laboratories and LENZ Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dr. Reddy’s Laboratories | 1 | 3 | 2 | 0 | 2.17 |
| LENZ Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Dr. Reddy’s Laboratories currently has a consensus target price of $492.90, suggesting a potential upside of 3,245.10%. LENZ Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 401.58%. Given Dr. Reddy’s Laboratories’ higher possible upside, equities research analysts clearly believe Dr. Reddy’s Laboratories is more favorable than LENZ Therapeutics.
Earnings & Valuation
This table compares Dr. Reddy’s Laboratories and LENZ Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dr. Reddy’s Laboratories | $3.58 billion | 3.44 | $456.00 million | $0.37 | 39.82 |
| LENZ Therapeutics | $19.09 million | 5.74 | -$82.13 million | ($4.49) | -0.78 |
Dr. Reddy’s Laboratories has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
Dr. Reddy’s Laboratories beats LENZ Therapeutics on 8 of the 14 factors compared between the two stocks.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
